Fc‐Dependent Targeting of the GAS6–MERTK Axis With Monoclonal and Bispecific Antibodies Overcomes Drug Resistance Across EGFR Mutations in Exons 19, 20, and 21
Suvendu Giri, Boobash Raj Selvadurai, Nitin Gupta, Arturo Simoni‐Nieves, Alessandro Genna, Moshit Lindzen, Rishita Chatterjee, Marieke Van Daele, Deepthi Ramesh Kumar, Mirie Zerbib, Roni Oren, Isabelle Sophie Meijer, Elisabeth Franziska Wippich, Yahel Avraham, Rony Dahan, Yuya Haga, Laura E. Kilpatr · 2026
Read Fc‐Dependent Targeting of the GAS6–MERTK Axis With Monoclonal and Bispecific Antibodies Overcomes Drug Resistance Across EGFR Mutations in Exons 19, 20, and 21 by Suvendu Giri, Boobash Raj Selvadurai, Nitin Gupta, Arturo Simoni‐Nieves, Alessandro Genna, Moshit Lindzen, Rishita Chatterjee, Marieke Van Daele, Deepthi Ramesh Kumar, Mirie Zerbib, Roni Oren, Isabelle Sophie Meijer, Elisabeth Franziska Wippich, Yahel Avraham, Rony Dahan, Yuya Haga, Laura E. Kilpatr (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13669479.txt.
Description
Suvendu Giri and a large team report a new antibody strategy against lung cancers that stop responding to EGFR-blocking drugs such as osimertinib. Re-reading clinical data, they found the signal GAS6 and its receptor MERTK raised in patients whose tumors resisted the drug. Extra GAS6 helped cancer cells survive, while a new antibody against it delayed relapse in mouse grafts. Removing MERTK made cells sensitive to osimertinib again, exposing cross-talk between the two receptors.
The team built an antibody against MERTK and a two-armed antibody, Bis-EM, that hits both receptors and drives their breakdown. It also helped immune cells kill tumor cells. With the blocking drugs, Bis-EM shrank resistant cell clusters and delayed relapse in patient-derived grafts, including hard exon 20 insertion cases. The effect depended on the antibody tail region. The authors argue Bis-EM merits clinical development.
Catalog record
| CREATOR | Suvendu Giri, Boobash Raj Selvadurai, Nitin Gupta, Arturo Simoni‐Nieves, Alessandro Genna, Moshit Lindzen, Rishita Chatterjee, Marieke Van Daele, Deepthi Ramesh Kumar, Mirie Zerbib, Roni Oren, Isabelle Sophie Meijer, Elisabeth Franziska Wippich, Yahel Avraham, Rony Dahan, Yuya Haga, Laura E. Kilpatr |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 94 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |